Technology
Our pipeline forms a robust portfolio of investigational
therapies in varied stages of clinical development.
LAPSCOVERY PENTAMBODY Cancer Research IMD•New Formulation

LAPSCOVERYTM

What is LAPSCOVERYTM?
Long Acting Protein / Peptide Discovery Platform Technology

Biologics have a short half-life when administered to the human body. This results in the need for frequent injections and inconvenience to patients. LAPSCOVERYTM (Long Acting Protein/Peptide Discovery) is a platform technology that prolongs the duration of action of biologics and makes it possible for once-weekly or monthly drug administration.

zoom
Longer Duration

Monomeric from helps to reduce receptor mediated clearance

FcRn mediated endothelium recycling / Avoiding renal filtration

Efficacy ⬆   Side Effects ⬇

Flexible linker minimaizes loss of intrinsic activity

Monomeric from helpls to reduce RMC

Highest bioavailability reduces dose level

Hanmi’s LAPSCOVERY™ technology prolongs the residence time of a biologic and also minimizes the frequency of treatment and dose required, thereby leading to potential optimized efficacy and reduced adverse events.

Hanmi’s
LAPSCOVERY VIDEO